Home > Healthcare > Pharmaceuticals > Finished Drug Form > Methicillin-resistant Staphylococcus Aureus Drugs Market
Methicillin-resistant Staphylococcus Aureus Drugs Market Trends
- Report ID: GMI9303
- Published Date: Apr 2024
- Report Format: PDF
Methicillin-resistant Staphylococcus Aureus Drugs Market Trends
- Increasing incidence of methicillin-resistant staphylococcus aureus (MRSA) infections is a significant growth driver for the market. For instance, according to the Centers for Disease Control and Prevention, there are more than 80,000 cases of MRSA each year, and more than 11,000 people die from these infections. Similarly, as per a study published by National Institute of Health (NIH), the pooled global prevalence of MRSA was 14.69%
- Thus, as the incidence of MRSA infections continues to rise globally, there is a growing need for effective treatment options, driving the demand for MRSA drugs.
- Pharmaceutical companies are investing in research and development to develop new antibiotics and therapies to combat MRSA, contributing to the growth of the MRSA drugs market.
- Additionally, the increasing awareness about MRSA and its potential complications among healthcare professionals and the public is also driving market growth, as early detection and treatment are crucial in managing MRSA infections.
Frequently Asked Questions (FAQ) :
The global methicillin-resistant staphylococcus aureus (MSRA) drugs market was valued at USD 4.1 billion in 2023 and is anticipated to grow at 4.2% CAGR between 2024
The glycopeptides segment in the MSRA drugs market reached USD 1.2 billion in 2023, owing to their broad-spectrum activity against gram-positive bacteria, including MRSA, and their established efficacy in treating severe MRSA infections.
North America methicillin-resistant staphylococcus aureus drugs market is anticipated to grow at 3.9% CAGR till 2032, attributed to advanced healthcare infrastructure, high awareness levels about infectious diseases, and robust research and development activities.
AbbVie Inc., Basilea Pharmaceutica Ltd, Baxter International Inc., Cumberland Pharmaceuticals Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.
Methicillin-resistant Staphylococcus Aureus Drugs Market Scope
×
Get a free sample of
Methicillin-resistant Staphylococcus Aureus Drugs Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below